Respiratory syncytial virus (RSV) causes a spectrum of respiratory illnesses in infants and
young children that may lead to hospitalizations and a substantial number of outpatient …

Maternal vaccination is an effective means of protecting pregnant women, their fetuses, and
infants from vaccine-preventable infections. Despite the availability of sufficient safety data to …

Respiratory syncytial virus (RSV) is responsible for a significant proportion of global
morbidity and mortality affecting young children and older adults. In the aftermath of formalin …

In May 2023, the US FDA advisors endorsed Pfizer's pregnancy-administered vaccine
(branded ABRYSVO) to protect infants from respiratory syncytial virus (RSV) infection …

Background Respiratory syncytial virus (RSV) remains a leading cause of pediatric
morbidity, with no approved vaccine. We assessed the safety and immunogenicity of the …

Respiratory syncytial virus (RSV) is a leading cause of hospitalization and infant mortality
worldwide. There are currently no approved vaccines against RSV, and immunoprophylaxis …

Respiratory syncytial virus (RSV) infects nearly all infants at least once by their second
birthday (1). It spreads through coughs, sneezes, or close physical contact (2). RSV …

Newly approved subunit and mRNA vaccines for respiratory syncytial virus (RSV)
demonstrate effectiveness in preventing severe disease, with protection exceeding 80 …

There is a major unmet need for strategies to improve the immunogenicity and effectiveness
of pandemic influenza vaccines, particularly in poor responder populations such as …

Respiratory syncytial virus (RSV) is a major global pathogen, causing lower respiratory tract
disease in at-risk populations including young children. Antibodies form a crucial layer of …